Cofece, Mexico’s antitrust commission, objected to the merger of the pharmaceutical companies Sanofi and Boehringer Ingelheim International in the animal health sector, considering that competition in five animal vaccine markets in Mexico would be at risk.
The agency said that the proposed merger consists of Boehringer acquiring the animal health business that Sanofi operates in Mexico, a transaction that is part of an international transaction agreed on by both companies.
Cofece explained that in this merger, both companies agreed on the commercialization of various vaccines and medicines indicated for poultry, pigs, cattle, goats and sheep, and others.
To ensure that competitive conditions will remain in all five markets, Cofece ruled that the transaction would only be authorized if the companies agreed to the divestment of four Boehringer and one Sanofi vaccine to a third party.
Full Content: El Economista
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
